The FDA approved copper histidinate (Zycubo) as the first treatment for Menkes disease in pediatric patients, the agency ...
Peanut oral immunotherapy is generally safe, but rare, severe immediate allergic reactions may emerge months into treatment, ...
A significantly higher proportion of 4- to 7-year-olds with peanut allergy using the Viaskin Peanut patch were deemed ...
Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectively Full Year 2026 target total global revenue of approximately ...
An oncology pharmacist shares how a treatment takes a different approach to treating chronic graft-versus-host disease (GVHD) ...
Align Technology explains why bridging the gap between clinical planning and emotional connection is key for treatment ...
A shocking video from Uttar Pradesh’s Mathura shows a man pulling a snake out of his jacket inside a government hospital, ...
New research finds a significantly lower dose of peanut oral immunotherapy may provide similar protection from accidental ...
ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire ...
Verywell Health on MSN
3 Rare But Serious Side Effects of Vitamin B12 Supplements
Vitamin B12 is typically well-tolerated, but in very rare cases, there are serious side effects to be aware of. Learn more ...
Learn more about peanut oral immunotherapy (OIT) and how lowering the treatment dose could help children with peanut ...
4hon MSN
Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy
According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback